Alteplase Dosing for Pulmonary Embolism in Adults
For adults with acute pulmonary embolism requiring thrombolysis, the FDA-approved and guideline-recommended dose of alteplase is 100 mg administered intravenously over 2 hours. 1, 2
Standard Dosing by Clinical Presentation
Massive PE (High-Risk with Hemodynamic Instability)
- Standard regimen: 100 mg IV infused over 2 hours 1
- Emergency/cardiac arrest: 50 mg IV bolus, with reassessment at 30 minutes 1
- Accelerated regimen (when massive PE confirmed in stable patients): 100 mg over 90 minutes (same as accelerated MI regimen) 1
The American Heart Association specifically recommends administration via peripheral intravenous catheter, with anticoagulation withheld during the 2-hour infusion period per FDA guidance 1
Submassive PE (Intermediate-Risk)
- Standard dose: 100 mg IV over 2 hours when thrombolysis is indicated 1
- Thrombolysis should be considered only in patients with evidence of moderate-to-severe RV strain (RV hypokinesis, estimated RVSP >40 mmHg, or significantly elevated troponin/BNP) AND signs of shock or respiratory failure (hypotension with SBP <90 mmHg, shock index >1.0, or SaO₂ <95% with respiratory distress) 1
Alternative Dosing Regimens
Reduced-Dose Alteplase
While the FDA-approved dose remains 100 mg over 2 hours, emerging evidence suggests reduced-dose regimens may offer similar efficacy with improved safety:
- 50 mg regimen: 50 mg IV over 2 hours has shown comparable efficacy to 100 mg with significantly fewer major bleeding complications (1.1% vs 6.1%, p=0.022) 3
- Weight-based bolus: 0.6 mg/kg (maximum 50 mg) over 15 minutes demonstrated 91.2% survival to discharge with only 1.3% major bleeding in a Vietnamese case series 4
- A meta-analysis found reduced-dose alteplase (0.6 mg/kg up to 50 mg, or fixed 50 mg) had similar efficacy but was safer than standard 100 mg dosing (OR 0.33 for major bleeding, 95% CI 0.12-0.91) 5
Important caveat: These reduced-dose regimens are not FDA-approved and represent off-label use, though they are increasingly utilized in clinical practice based on observational data 5, 3
Catheter-Directed Thrombolysis
For catheter-directed approaches, substantially lower doses are used:
- Adult dosing: 0.5-1 mg/hour via catheter, typically totaling 20-24 mg (approximately one-fourth of systemic dose) 1
- The goal is to achieve similar effectiveness while minimizing bleeding risk through direct delivery into the pulmonary artery thrombus 1
Critical Safety Considerations
Concomitant Anticoagulation
- During infusion: FDA recommends withholding anticoagulation during the 2-hour alteplase infusion 1
- After thrombolysis: Resume unfractionated heparin 3 hours after completion, preferably weight-adjusted 1
- Excessive anticoagulation levels were associated with 37.5% of hemorrhagic complications in one large series 3
Bleeding Risk Management
- Major bleeding occurs in approximately 6-24% of patients with full-dose alteplase 3
- Avoid invasive procedures when possible (associated with 31.3% of bleeding complications) 3
- Intracranial hemorrhage risk is approximately 1-2% with standard dosing 5, 3
Pharmacokinetics
- Plasma clearance occurs with initial half-life <5 minutes and terminal half-life of 72 minutes 2
- Clearance is mediated primarily by the liver 2
Clinical Decision Algorithm
For massive PE with shock/cardiac arrest: Use 50-100 mg alteplase immediately, do not delay for imaging if clinical suspicion is high and RV dysfunction is evident on bedside echo 1
For confirmed massive PE in stable patients: Use 100 mg over 90 minutes 1
For submassive PE: Only consider thrombolysis if BOTH criteria are met: (1) moderate-to-severe RV strain on imaging/biomarkers AND (2) evidence of hemodynamic or respiratory compromise 1
For low-risk PE: Thrombolysis is not recommended; use anticoagulation alone 1